This document discusses over-the-counter (OTC) drugs and regulations regarding OTC drugs in India, the United States, and Europe. It defines OTC drugs as drugs that can be purchased without a prescription and are considered safe for self-treatment. The key points covered include: OTC drug schedules in India, examples of common OTC drugs, regulations governing labeling, advertising and distribution of OTC drugs in each region, and processes for switching a drug from prescription to OTC status. Comparisons are made between the regulatory approaches in different jurisdictions.
Introduction to daily activities of clinical pharmacist.
Drug therapy monitoring,
Medication chart review
Clinical Progress
Pharmacist intervention
Detection and management of ADRs
Introduction to daily activities of clinical pharmacist.
Drug therapy monitoring,
Medication chart review
Clinical Progress
Pharmacist intervention
Detection and management of ADRs
Slides includes ADR monitoring process, Safety reporting, what is pharmacovigilance, types of ADR, basic terms in ADR monitoring, what is PvPI in India, role. stakeholders, ADR reporting form, Apps, Role of community Pharmacist in ADR monitoring, Importance of ADR monitoring, etc.
REVIEWING THE CLINICIANS PRESCRIPTION AND TREATMENT PROGRESSION IS THE FUNDAMENTAL RESPONSIBILITY OF PHARMACIST. THIS PRESENTATION WILL DEAL WITH VARIOUS ASPECTS OF REVIEWING PATIENT DRUGTHERAPY PLAN
PHARMACIST ROLE IN COMMUNITY PHARMACY , OTC GUIDELINES , PRESCRIPTION PRECAU...VENKATA RAMA RAO NALLANI
IT has covered choice medicine by cost ,taste, safety, Prescription precautions, COMMUNITY PHARMACY AND CLINICAL PHARMACIST RESPONSIBILITIES IN IN PATIENT CARE
Slides includes ADR monitoring process, Safety reporting, what is pharmacovigilance, types of ADR, basic terms in ADR monitoring, what is PvPI in India, role. stakeholders, ADR reporting form, Apps, Role of community Pharmacist in ADR monitoring, Importance of ADR monitoring, etc.
REVIEWING THE CLINICIANS PRESCRIPTION AND TREATMENT PROGRESSION IS THE FUNDAMENTAL RESPONSIBILITY OF PHARMACIST. THIS PRESENTATION WILL DEAL WITH VARIOUS ASPECTS OF REVIEWING PATIENT DRUGTHERAPY PLAN
PHARMACIST ROLE IN COMMUNITY PHARMACY , OTC GUIDELINES , PRESCRIPTION PRECAU...VENKATA RAMA RAO NALLANI
IT has covered choice medicine by cost ,taste, safety, Prescription precautions, COMMUNITY PHARMACY AND CLINICAL PHARMACIST RESPONSIBILITIES IN IN PATIENT CARE
OTC Drug marketing is a different ball game all together than the ethical sales promotional model, being used by the pharmaceuticals companies. As the core idea of OTC Drugs marketing is pushing of sales, the sales promotion model has to be different. This presentation outlines a sales promotional model for the OTC Drug marketers in India.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.Audumbar Mali
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
B. Pharm. Final Year, Sem-VIII, BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory),
As PCI Syllabus.
Pharmaceutical Jurisprudence SCHEDULES
By_ Nakul Dhore
❖Schedules to the Act (02)
❖Schedules to the Rules (23)
❖Appendices (06)
❖Important Acts & Years
❖Multiple Choice Questions
Pharmaceutical Jurisprudence
Semester 5
As Per PCI Syllabus (New)
Introduction to D & C Act 1940 and Rules 1945, Definitions, Various Schedules in D & C Rules 1945, Administration of the act and rules, Manufacturing , Distribution and sale of drug and cosmetic, Labeling and Packing of drug and cosmetic.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
2. DEFINITION
OTC Drugs are drugs that have been found to be safe and
appropriate for use without the supervision of a health care
professional such as a physician, and they can be purchased by
consumers without a prescription.
Self treat
Self-diagnose
Self manage
Advertised.
3. At present, there is no OTC schedule in the Drugs and
Cosmetics Rules 1945.
Hence, any drug outside schedule H, G and X is considered to
be an OTC drug.
1. SCHEDULE K
Household remedies
Item No.13
Form 20 A
Form 20B
4. Examples
Aspirin tablets, Antacid preparation, Analgesic balm etc.
Cold and nasal congestion preparations &
syrups, lozenges, pills and tablets for cough.
Digene (antacid)
Paracetamol
5. 2. Exemption of Schedules G, H or X
Topical or external use (except ophthalmic and ear / nose
preparations containing antibiotics and / or steroids)
applications of the ingredients from these schedule.
Clause – 2 : The salts, esters, derivatives and preparations
containing the above substances excluding those intended for
topical or external use.
7. 3. AYURVEDIC OTC DRUGS
The Ayurvedic State Licensing Authorities.
Examples
Vicks VapoRub,
Amrutanjan Pain Balm,
Zandu Pain Balm,
Iodex Pain Balm,
Moov Pain Cream,
Itch Guard Cream,
Eno Fruit Salt antacid
8. 1. The Drugs and Cosmetics Act, 1940 (DCA) and its
subordinate legislation, the Drugs and Cosmetics Rules, 1945
(DCR).
2. Other regulations are which have a bearing on the
pharmaceutical business in India;
Drug (Prices Control) Order, 1995,
Example; Acetylsalicylic acid And Ephedrine
Drugs (Magic Remedies) Objectionable Advertisement
Act, 1954
9. 1.Rule 96 of the DCR
2. Rule 97
3. Maximum Retail Price (MRP) printed on the label.
The Standards of Weights & Measures Act
(Packaged Commodities)
4.Warnings
5. Symbols (Rx, X )
6. Rule 161
10. Non Prescription(OTC) Registration
Single or combination containing non-prescription drugs, i.e. out
of Schedule G,H or X cannot be directly granted as OTC.
First it will be approved as Rx (prescription) and later on
application is required to be filed for switch from Rx to OTC.
11. In the United States the manufacturing & sale OTC drug product
is regulated by, USFDA
OTC Drug Product Allowed to be marketed either:
(1) Pursuant to an FDA OTC monograph; or
(2) Pursuant to an NDA for products that do not fit within a
specific monograph
12. Types of NDAs
1. Rx to OTC switches
Full switch (NDA supplement).
Partial switch (new NDA).
2. Direct to OTC
NDA deviation ( NDA deviation (330.11))
Generic (ANDA)
13. Division of Non-prescription regulation
Development(DNRD) in ODE IV.
“Recipe book” for marketing an OTC drug
„ „ A list and explanation of GRASE conditions
GRASE = Generally Recognized As Safe and Effective
„ „ Final monographs are published in Code of Federal
Regulations: 21 CFR parts 331-358
14. §331.10 Active
ingredients…Calcium, as carbonate
or phosphate; maximum daily
dosage limit 160mEq. calcium
(e.g., 8 grams calcium carbonate
331.30(b) Indications…‘‘For the
relief of’’ (optional, any or all of
the following:) ‘‘heartburn,’’ ‘‘sour
stomach, 'and/or ‘‘acid
indigestion’’
331.30(c) Warnings…“Do not take
more than (max. rec. daily dosage)
in a 24-hour period, or use the
maximum dosage of this product
for more than 2 weeks
15. Restricted OTC Substances
Examples;
1. Methamphetamine
The Methamphetamine Precursor Control Act
A House Bill 512 passed in the State Senate on
February 2,2010
2. Preventing Abuse Of cough treatment Act (PACT Act)
Dextromethorphan
3. Emergency Contraceptive
16. 1. 21 CFR 201.66 for labelling requirement of OTC product in
US.
2. Drug Facts
Standardized labelling format Similar to “Nutrition Facts”
& “Supplement Facts”
3. Federal Trade Commission (FTC)
4. National Advertisement Division
18. The main directives regarding medical products for human use
are as follows:
2001/83/EC
Articles 70-75 of Directive 2001/83/EC have been reserved
for classification of medical products for human use.
Article 70 stated that when a marketing authorization is
granted, the competent authorities should specify the
classification of the medical product as one subject to medical
prescription, or as one not subject to medical prescription.
19. 1. Article 71 State that; Criteria to be use for classification of
medicinal product, Established With purpose to prioritize
patient safety.
Prescription drugs
Subjected to be Danger
Used incorrectly
Side effect
Administered parenterally
2. Article 72
20. 1. DIRECT PROMOTION TO CONSUMERS
Article 88 of the Directive 2001/83/EC dated November 6, 2001
2. OTC LABELLING REQUIREMENT
Articles 54-69 of the directive 2001/83/EC are reserved for
the labelling and prospectuses of medical products for human
use.
21. Article 54,55,59 of Directive 2001/83/EC
Article 62 of Directive 2001/83/EC
Title V of the Directive 2001/83/EC
Articles listing the requirements relating to the contents of the
labelling and package.
22. S.N
O
Key point consideration US FDA INDIA EUROPE
1. OTC NDAAPPLICATION Us FDA Drug & cosmetic act
1940 (For
prescription drugs)
2001/83/EC
2. OTC MONOGRAPH The Division of Non-
prescription Regulation
Development (DNRD
NA NA
3. LABELLING
REQUIREMENT 21CFR 201.66
NO Separate
requirement
Articles 54-69 of
the directive
2001/83/EC
4. ADVERTIZMENT Federal Trade Commission
(FTC)
Magic remedies act
1954
Article 88 of the
Directive
2001/83/EC
5. DISTRIBUTION Supermarket Generaly small
independent shop
Supermarket/ even at
fuel station
6. SWITC RX TO OTC Drug review panel Lacks such system Directive
2004/27/EC
7. PRICE CONTROL NA DPCO 1995 89/105/EEC
(TRANPERENCY
DIRECTIVE)
23. UNITED STATE
The manufacturer requests the switch by submitting a
supplemental application to its approved NDA.
• A petition from the manufacturer to the FDA.
• Recommendation from the OTC review panel
EUROPE
Article 74a of Directive 2001/83/EC amended by 2004/27/EC
• significant preclinical trails and clinical trial
• Data exclusivity
24. INGREDIENT ADULT DOSAGE PRODUCT CATEGORY DATE OF OTC
APPROVAL
PRODUCT EXAMPLES
1 Ibuprofen and
phenylephrineHCl
(NDA)
200mg
ibuprofen and
10mg
phenylephrine
HCl
analgesic/decon
gestant
May 27, 2010 Advil
Congestion
Relief (Pfizer)
2 Fexofenadine
hydrochloride (NDA)
30 mg; 60 mg;
180 mg 30 mg/5
Ml
Antihistamine January 24,
2011
Allegra
(Chattem)
3 Fexofenadine
hydrochloride and
pseudoephedrine HCl
(NDA)
180 mg; 240 mg antihistamine/
decongestant
January 24,
2011
Allegra D 12-
Hour (Chattem)
4 Fexofenadine
hydrochloride and
pseudoephedrine HCl
(NDA)
antihistamine/
decongestant
January 24,
2011
Allegra D 24-
Hour (Chattem)
5 Oxybutynin (NDA) 3.9 mg overactive
bladder
January 25,
2013
Oxytrol for
Women (Merck)
25. Regulation requirement
• Reduce drug abuse
• Improve patient safety
Comparatively study
India is one of emerging country require separate criteria for
“OTC REGULATION” for enhance patient safety and reduce
Drug abuse.
ORGANISATION OF PHARMACEUTICAL PRODUCERS
(OPPI) works toward the promotion of OTC in INDIA.